Form 4: Phathom Pharmaceuticals Director Mark Stenhouse Receives Significant Equity Compensation Grant

Phathom Pharmaceuticals, Inc. Director Mark Stenhouse was granted 10,500 Restricted Stock Units and 17,500 stock options as part of the company's Non-Employee Director Compensation Program.

Summary

• Mark Stenhouse, a Director of Phathom Pharmaceuticals, Inc. (PHAT), received equity compensation on June 3, 2025.
• He was granted 10,500 Restricted Stock Units (RSUs) at a price of $0, with each RSU representing a contingent right to receive one share of common stock.
• Additionally, he received 17,500 stock options with an exercise price of $4.95 per share.
• Both the RSUs and stock options are set to vest on the first anniversary of the grant date or the next annual meeting of stockholders, whichever occurs first, contingent upon his continued service on the Board.
• Following these transactions, Mark Stenhouse beneficially owns 30,000 shares of common stock and 17,500 stock options directly.

Sentiment

Score: 7

Explanation: The filing indicates a standard equity compensation grant to a director, which is generally a positive sign of aligning management interests with shareholders, but it does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• Director Mark Stenhouse received a significant equity grant, which aligns his interests with those of the company's shareholders.
• The grant is part of the Issuer's established Non-Employee Director Compensation Program, indicating a structured approach to board remuneration.

Risks

• The vesting of the granted Restricted Stock Units and stock options is contingent upon Mark Stenhouse's continued service on the Board through the specified vesting date, meaning the compensation is not guaranteed if his service ceases prematurely.

Future Outlook

The vesting of the granted Restricted Stock Units and stock options is contingent upon Mark Stenhouse's continued service on the Board of Directors until the first anniversary of the grant date or the next annual meeting of stockholders, whichever is earlier.

Management Comments

• The Restricted Stock Units and stock options were granted pursuant to the Issuer's Non-Employee Director Compensation Program.

Industry Context

Equity compensation, particularly through Restricted Stock Units and stock options, is a common and widely accepted practice in the biotechnology and pharmaceutical industries. It serves to attract and retain experienced directors and align their long-term interests with the company's performance and shareholder value creation.

Comparison to Industry Standards

• The grant of RSUs and stock options to a non-employee director is a standard compensation practice across the pharmaceutical and biotech sectors, comparable to programs at companies like BioNTech SE or Moderna, Inc., which also utilize equity-based incentives to compensate their board members and align their interests with company performance and shareholder returns.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant to a director further aligns his financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• Vesting of RSUs and stock options on the first anniversary of June 3, 2025, or the next annual meeting of stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, SEC filing, Director compensation, Restricted Stock Units, RSUs, Stock options, Equity grant, Insider transaction, Mark Stenhouse